Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:3795-3801
Published online before print December 5, 2005, doi: 10.1161/CIRCULATIONAHA.105.556233
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v113,pe712)
Right arrow All Versions of this Article:
112/24/3795    most recent
CIRCULATIONAHA.105.556233v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mason, R. P.
Right arrow Articles by Malinski, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mason, R. P.
Right arrow Articles by Malinski, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

(Circulation. 2005;112:3795-3801.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans

R. Preston Mason, PhD; Leszek Kalinowski, MD, PhD; Robert F. Jacob, PhD; Adam M. Jacoby, BS; Tadeusz Malinski, PhD

From the Department of Biochemistry, Ohio University, Athens, Ohio (L.K., A.M.J., T.M.); Elucida Research, Beverly, Mass (R.P.M., R.F.J.); and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (R.P.M.). Dr Kalinowski was on sabbatical leave from the University of Gdansk.

Correspondence to Tadeusz Malinski, PhD, Department of Biochemistry, Ohio University, 350 W State St, Athens, OH 45701. E-mail malinski{at}ohiou.edu

Received April 15, 2005; revision received August 8, 2005; accepted September 19, 2005.

Background— Alterations in endothelial function may contribute to increased susceptibility of black Americans to cardiovascular disease. The ability to pharmacologically reverse endothelial dysfunction in blacks was tested with nebivolol, a ß1-selective agent with vasodilating and antioxidant properties.

Methods and Results— The effects of nebivolol on endothelial nitric oxide (NO), superoxide (O2), and peroxynitrite concentration (ONOO) release were studied in human umbilical vein endothelial cells and iliac artery endothelial cells isolated from age-matched black and white donors. Kinetics and concentrations of NO/O2/ONOO were measured simultaneously with nanosensors from single cells and shown to have significant interracial differences. The rate of NO release was &5 times slower in blacks than in whites (94 versus 505 nmol · L–1 · s–1), whereas the rates of release were faster by &2 times for O2 and &4 times for ONOO (22.1 versus 9.4 nmol · L–1 · s–1 for O2 and 810 versus 209 nmol · L–1 · s–1 for ONOO). Pretreatment with 1.0 to 5.0 µmol/L nebivolol restored NO bioavailability in endothelial cells from black donors with concurrent reductions in O2 and ONOO release, similar to levels in the endothelium of whites. The effects of nebivolol were dose-dependent and not observed with atenolol; similar effects were observed with apocynin, an NAD(P)H oxidase inhibitor.

Conclusions— Reduced endothelial NO bioavailability in American blacks is mainly due to excessive O2 and ONOO generation by NAD(P)H and uncoupled endothelial NO synthase. Nebivolol decreased O2 and ONOO concentrations and restored NO bioavailability in blacks to the level recorded in cells from whites, independently of ß1-selective blockade.


Key Words: cardiovascular diseases • endothelium • nitric oxide • beta-blockers • ethnic groups




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
L. M. Prisant
Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker
J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Hallstrom, M. Franz, H. Gasser, M. Vodrazka, S. Semsroth, U. M. Losert, M. Haisjackl, B. K. Podesser, and T. Malinski
S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart after unprotected warm ischaemia
Cardiovasc Res, February 1, 2008; 77(3): 506 - 514.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
E. Mata-Greenwood and D.-B. Chen
Racial Differences in Nitric Oxide--Dependent Vasorelaxation
Reproductive Sciences, January 1, 2008; 15(1): 9 - 25.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
G. Peluffo and R. Radi
Biochemistry of protein tyrosine nitration in cardiovascular pathology
Cardiovasc Res, July 15, 2007; 75(2): 291 - 302.
[Abstract] [Full Text] [PDF]